These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21785952)

  • 1. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations.
    Lee S; Ahn HK; Park YH; Nam DH; Lee JI; Park W; Choi DH; Huh SJ; Park KT; Ahn JS; Im YH
    Breast Cancer Res Treat; 2011 Oct; 129(3):809-17. PubMed ID: 21785952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.
    Jang G; Lee SS; Ahn JH; Jung KH; Lee H; Gong G; Kim HH; Ahn SD; Son BH; Ahn SH; Kim SB
    Breast Cancer Res Treat; 2011 Jul; 128(1):171-7. PubMed ID: 21519835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.
    Morikawa A; Jordan L; Rozner R; Patil S; Boire A; Pentsova E; Seidman AD
    Clin Breast Cancer; 2017 Feb; 17(1):23-28. PubMed ID: 27569275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between EGFR overexpression and skin manifestations.
    Kong JH; Park YH; Kim JA; Kim JH; Yun J; Sun JM; Won YW; Lee S; Kim ST; Cho EY; Ahn JS; Im YH
    Oncology; 2011; 81(1):55-62. PubMed ID: 21934337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
    Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
    Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience.
    Jo JC; Kang MJ; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Ahn SD; Kim SS; Son BH; Ahn SH; Kim SB
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):201-7. PubMed ID: 23670641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer.
    Choi MK; Park YH; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):521-9. PubMed ID: 25047725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged survival of patients with breast cancer-related leptomeningeal metastases.
    Le Rhun E; Taillibert S; Zairi F; Pannier D; Boulanger T; Andre C; Cazin JL; Dubois F; Bonneterre J; Chamberlain MC
    Anticancer Res; 2013 May; 33(5):2057-63. PubMed ID: 23645756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
    Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study.
    Huppert LA; Fisch S; Tsopurashvili E; Somepalle SS; Salans M; Vasudevan HN; Jo Chien A; Majure M; Rugo HS; Balassanian R; Boreta L; Melisko ME
    Breast Cancer Res Treat; 2024 Aug; 206(3):625-636. PubMed ID: 38888796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
    Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
    Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
    Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
    Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics and prognosis of different subtypes of breast cancer].
    Yuan ZY; Wang SS; Zhu MQ; Zheng L; Luo WB; Zhou ZM; Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):456-61. PubMed ID: 19024523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary and secondary distant metastatic breast cancer: two sides of the same coin.
    Güth U; Magaton I; Huang DJ; Fisher R; Schötzau A; Vetter M
    Breast; 2014 Feb; 23(1):26-32. PubMed ID: 24215983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.
    Zaky SS; Lund M; May KA; Godette KD; Beitler JJ; Holmes LR; O'Regan RM; Yu ES; Yu DS; Landry JC
    Ann Surg Oncol; 2011 Oct; 18(10):2858-65. PubMed ID: 21442346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.